Co-Diagnostics to Present on Co-Dx™ PCR Platform and AI Integration at Point-of-Care Testing 2025

Rhea-AI Summary

Co-Diagnostics (Nasdaq: CODX) announced it will present at Point-of-Care Testing 2025 in Boston on Dec. 9, 2025. The presentation, titled "Exploring the Promise of Portable, Cloud-Connected PCR Diagnostics," will describe the company's move to portable PCR devices, the upcoming Co-Dx PCR platform (including Co-Dx PCR Home and Co-Dx PCR Pro), an intuitive smartphone interface, and the integration of AI to reduce user error and improve real-time point-of-care outcomes.

The speaker session is scheduled for 11:30 AM EST at the Boston Marriott Cambridge. The summary notes the Co-Dx PCR platform and associated tests/software remain subject to FDA and other regulatory review and are not available for sale.

Argus Dec 9 session

+4.55% close to close 0.7x rel. volume Open Argus

Details

News Market Reaction – CODX

On Dec 9, the day this news came out, CODX closed 4.55% above the previous close.

Data tracked by StockTitan Argus for the Dec 9 session.

Key Figures

Presentation time: 11:30 AM EST

Presentation time

11:30 AM EST

Point-of-Care Testing 2025 conference session in Boston

Historical Context

5 past events · Latest: Nov 20

5 events

1. Nov 20

   TB test update

   24h Move

   -5.8%

   Highlighted upcoming MTB PoC test and potential expansion into India and South Africa.

2. Nov 18

   Clinical evaluations

   24h Move

   +13.4%

   Initiated clinical evaluations for upper respiratory multiplex test to support FDA 510(k).

3. Nov 13

   Q3 2025 earnings

   24h Move

   -6.1%

   Reported sharp revenue decline, operating loss, and reliance on recent financings.

4. Nov 12

   JV recognition

   24h Move

   +0.7%

   Recognition by Utah leadership following CoMira JV announcement in Saudi Arabia.

5. Nov 05

   SPAC exploration

   24h Move

   +3.5%

   Engaged Maxim Group to explore SPAC or similar transaction for CoSara JV.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pcr, point-of-care testing, ai, fda

4 terms

pcr medical

"Exploring the Promise of Portable, Cloud-Connected PCR Diagnostics"

PCR (polymerase chain reaction) is a laboratory method that makes many copies of a tiny piece of genetic material (DNA or RNA) so scientists can detect and study it reliably — think of photocopying a faint, tiny note until the words are easy to read. For investors, PCR matters because it underpins diagnostic tests, drug development, and biotech tools whose sales, regulatory approvals, and real-world use can materially affect company revenues and market perceptions during health events or product launches.

point-of-care testing medical

"the Point-of-Care Testing 2025 Exhibition and Conference in Boston"

Medical tests performed at or near the site of patient care that produce rapid results without sending samples to a distant laboratory — like using a point-of-care glucose meter instead of waiting for lab work. Investors care because these tests speed treatment decisions, can lower care costs and expand the number of tests performed, creating demand for devices, supplies and software; sales hinge on accuracy, insurance coverage and regulatory approval.

ai technical

"discuss how Co-Dx is harnessing AI to minimize user error"

Artificial intelligence (AI) is technology that enables machines to mimic human thinking and learning, allowing them to analyze information, recognize patterns, and make decisions. For investors, AI matters because it can improve how businesses operate, create new products, or identify opportunities faster and more accurately than humans alone, potentially impacting company success and market trends.

fda regulatory

"subject to review by the FDA and/or other regulatory bodies"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SALT LAKE CITY, Dec. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Company is delivering a presentation at the Point-of-Care Testing 2025 Exhibition and Conference in Boston, MA.

The presentation, titled "Exploring the Promise of Portable, Cloud-Connected PCR Diagnostics," will unpack Co-Dx's move to portable PCR diagnostics to address evolving point-of-care needs, introduce the Company's upcoming Co-Dx PCR platform* and intuitive smartphone interface, and discuss how Co-Dx is harnessing AI to minimize user error and improve outcomes in real-time point-of-care testing.

The Conference provides a forum for industry leaders and healthcare innovators to explore the latest breakthroughs in diagnostic testing, advanced technologies, and clinical strategies driving the future of patient-centered care. Agenda topics include trends in point-of-care diagnostics and patient-centered care strategies, innovative platforms for mobile testing and real-time health monitoring, the integration of AI and digital platforms in next-generation diagnostics, and advanced testing kits for infectious and chronic disease management.

The speaker session will be held at 11:30 AM EST at the Boston Marriott Cambridge in Massachusetts.

*The Co-Dx PCR platform (including the Co-Dx PCR Home™, Co-Dx PCR Pro™, mobile app, and all associated tests and software) is subject to review by the FDA and/or other regulatory bodies and is not available for sale.

About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company's technologies are utilized for tests that are designed to detect and/or analyze nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform (subject to regulatory review and not currently for sale) and to identify genetic markers for use in applications other than infectious disease.

View original content to download multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-to-present-on-co-dx-pcr-platform-and-ai-integration-at-point-of-care-testing-2025-302636360.html

SOURCE Co-Diagnostics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Co-Diagnostics (CODX) present at Point-of-Care Testing 2025?

Co-Diagnostics will present on Dec. 9, 2025 at 11:30 AM EST at the Boston Marriott Cambridge.

What is the title of Co-Diagnostics' (CODX) presentation at the conference?

The presentation is titled "Exploring the Promise of Portable, Cloud-Connected PCR Diagnostics".

What products will Co-Diagnostics (CODX) discuss at Point-of-Care Testing 2025?

Co-Diagnostics will introduce its upcoming Co-Dx PCR platform, including Co-Dx PCR Home, Co-Dx PCR Pro, the mobile app, and associated tests and software.

How is Co-Diagnostics (CODX) integrating AI into its Co-Dx PCR platform?

Co-Diagnostics will discuss using AI to minimize user error and improve real-time point-of-care outcomes.

Is the Co-Dx PCR platform from Co-Diagnostics (CODX) available for sale now?

No. The Co-Dx PCR platform and associated tests/software are subject to FDA and other regulatory review and are not available for sale.